{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:24:56Z","timestamp":1792592696674,"version":"4.5.0"},"reference-count":137,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T00:00:00Z","timestamp":1691971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>An unprecedented global pandemic caused by a novel coronavirus named SARS-CoV-2 has created a severe healthcare threat and become one of the biggest challenges to human health and the global economy. As of July 2023, over 767 million confirmed cases of COVID-19 have been diagnosed, including more than 6.95 million deaths. The S protein of this novel coronavirus binds to the ACE2 receptor to enter the host cells with the help of another transmembrane protease TMPRSS2. Infected subjects that can mount an appropriate host immune response can quickly inhibit the spread of infection into the lower respiratory system and the disease may remain asymptomatic or a mild infection. The inability to mount a strong initial response can allow the virus to replicate unchecked and manifest as severe acute pneumonia or prolonged disease that may manifest as systemic disease manifested as viremia, excessive inflammation, multiple organ failure, and secondary bacterial infection among others, leading to delayed recovery, hospitalization, and even life-threatening consequences. The clinical management should be targeted to specific pathogenic mechanisms present at the specific phase of the disease. Here we summarize distinct phases of COVID-19 pathogenesis and appropriate therapeutic paradigms associated with the specific phase of COVID-19.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1116131","type":"journal-article","created":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T14:31:42Z","timestamp":1692023502000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":43,"title":["Pathophysiology and clinical management of coronavirus disease (COVID-19): a mini-review"],"prefix":"10.3389","volume":"14","author":[{"given":"Ying","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lokesh","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"B3","first-page":"3","article-title":"Properties of coronavirus and SARS-coV-2","volume":"42","author":"Malik","year":"2020","journal-title":"Malays J Pathol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27541","article-title":"OMICRON (B.1.1.529): A new SARS-CoV-2 variant of concern mounting worldwide fear","volume":"94","author":"Thakur","year":"2022","journal-title":"J Med Virol"},{"key":"B5","unstructured":""},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.1754","article-title":"Hospitalizations and mortality from non-SARS-coV-2 causes among medicare beneficiaries at US hospitals during the SARS-coV-2 pandemic","volume":"5","author":"Dang","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcaa202","article-title":"The impact of the COVID-19 pandemic on suicide rates","volume":"113","author":"Sher","year":"2020","journal-title":"QJM"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the chinese center for disease control and prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.04.021","article-title":"Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis","volume":"81","author":"Zheng","year":"2020","journal-title":"J Infect"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03553-9","article-title":"High-dimensional characterization of post-acute sequelae of COVID-19","volume":"594","author":"Al-Aly","year":"2021","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01283-z","article-title":"Post-acute COVID-19 syndrome","volume":"27","author":"Nalbandian","year":"2021","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.bbi.2021.12.020","article-title":"Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis","volume":"101","author":"Ceban","year":"2022","journal-title":"Brain Behav Immun"},{"key":"B13","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/s41579-023-00896-0","article-title":"Author Correction: Long COVID: major findings, mechanisms and recommendations","volume":"21","author":"Davis","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"5104","DOI":"10.1038\/s41467-022-32507-6","article-title":"A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity","volume":"13","author":"Kedor","year":"2022","journal-title":"Nat Commun"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1101\/2022.08.09.22278592","article-title":"Distinguishing features of Long COVID identified through immune profiling","author":"Klein","year":"2022","journal-title":"medRxiv"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2001899","article-title":"Evidence of SARS-coV-2 infection in returning travelers from wuhan, China","volume":"382","author":"Hoehl","year":"2020","journal-title":"N Engl J Med"},{"key":"B17","unstructured":"Protocol for prevention and control of COVID-19 (Trial edition 6)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-coV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1101\/2020.02.11.944462","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","author":"Wrapp","year":"2020","journal-title":"bioRxiv"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0868-6","article-title":"SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes","volume":"26","author":"Sungnak","year":"2020","journal-title":"Nat Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-020-0754-0","article-title":"Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection","volume":"14","author":"Zou","year":"2020","journal-title":"Front Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2019.197834","article-title":"Identification of the immunodominant neutralizing regions in the spike glycoprotein of porcine deltacoronavirus","volume":"276","author":"Chen","year":"2020","journal-title":"Virus Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202001-0179LE","article-title":"Single-cell RNA expression profiling of ACE2, the receptor of SARS-coV-2","volume":"202","author":"Zhao","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04802-1","article-title":"Inflammasome activation in infected macrophages drives COVID-19 pathology","volume":"606","author":"Sefik","year":"2022","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0869-5","article-title":"Temporal dynamics in viral shedding and transmissibility of COVID-19","volume":"26","author":"He","year":"2020","journal-title":"Nat Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2020-138577","article-title":"COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment","volume":"97","author":"Parasher","year":"2021","journal-title":"Postgrad Med J"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor recognition by the novel coronavirus from wuhan: an analysis based on decade-long structural studies of SARS coronavirus","volume":"94","author":"Wan","year":"2020","journal-title":"J Virol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.2565","article-title":"Presumed asymptomatic carrier transmission of COVID-19","volume":"323","author":"Bai","year":"2020","journal-title":"JAMA"},{"key":"B29","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13054-020-2817-7","article-title":"Familial cluster of COVID-19 infection from an asymptomatic","volume":"24","author":"Zhang","year":"2020","journal-title":"Crit Care"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2020.25.17.2000257","article-title":"Estimating the generation interval for coronavirus disease (COVID-19) based on symptom onset data, March 2020","volume":"25","author":"Ganyani","year":"2020","journal-title":"Euro Surveill"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12998","article-title":"Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and management","volume":"93","author":"Anka","year":"2021","journal-title":"Scand J Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04345-x","article-title":"Local and systemic responses to SARS-CoV-2 infection in children and adults","volume":"602","author":"Yoshida","year":"2022","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc6027","article-title":"Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients","volume":"369","author":"Hadjadj","year":"2020","journal-title":"Science"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.12839","article-title":"Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review","volume":"324","author":"Wiersinga","year":"2020","journal-title":"JAMA"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-06059-6","article-title":"Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation","volume":"46","author":"Leisman","year":"2020","journal-title":"Intensive Care Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.57555","article-title":"Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome","volume":"9","author":"van de Veerdonk","year":"2020","journal-title":"Elife"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26254","article-title":"Microstructure, pathophysiology, and potential therapeutics of COVID-19: A comprehensive review","volume":"93","author":"Singh","year":"2021","journal-title":"J Med Virol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s12250-020-00207-4","article-title":"Understanding SARS-coV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools","volume":"35","author":"Fu","year":"2020","journal-title":"Virol Sin"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30858-8","article-title":"Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed","volume":"395","author":"Feldmann","year":"2020","journal-title":"Lancet"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30416-1","article-title":"Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19","volume":"3","author":"Garbers","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30920-X","article-title":"SARS-CoV-2 and viral sepsis: observations and hypotheses","volume":"395","author":"Li","year":"2020","journal-title":"Lancet"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1746199","article-title":"Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia","volume":"9","author":"Lin","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"B44","first-page":"20","article-title":"COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management","volume":"29","author":"Ochani","year":"2021","journal-title":"Infez Med"},{"key":"B45","volume-title":"Features, evaluation, and treatment of coronavirus (COVID-19)","author":"Cascella","year":"2022"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-06062-x","article-title":"High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study","volume":"46","author":"Helms","year":"2020","journal-title":"Intensive Care Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.7326\/M20-2003","article-title":"Autopsy findings and venous thromboembolism in patients with COVID-19: A prospective cohort study","volume":"173","author":"Wichmann","year":"2020","journal-title":"Ann Intern Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30420-","article-title":"COVID-19 vasculitis and novel vasculitis mimics","volume":"3","author":"McGonagle","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-020-0413-9","article-title":"COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives","volume":"17","author":"Nishiga","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00536-9","article-title":"Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19","volume":"21","author":"Bonaventura","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","article-title":"Imbalanced host response to SARS-coV-2 drives development of COVID-19","volume":"181","author":"Blanco-Melo","year":"2020","journal-title":"Cell"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.07.005","article-title":"Lessons for COVID-19 immunity from other coronavirus infections","volume":"53","author":"Sariol","year":"2020","journal-title":"Immunity"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01331-15","article-title":"The nucleocapsid protein of coronaviruses acts as a viral suppressor of RNA silencing in mamMalian cells","volume":"89","author":"Cui","year":"2015","journal-title":"J Virol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01275-13","article-title":"Characterization of a critical interaction between the coronavirus nucleocapsid protein and nonstructural protein 3 of the viral replicase-transcriptase complex","volume":"87","author":"Hurst","year":"2013","journal-title":"J Virol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12879-020-05730-z","article-title":"JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis","volume":"21","author":"Walz","year":"2021","journal-title":"BMC Infect Dis"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/7527953","article-title":"Neutrophil extracellular traps (NETs) and damage-associated molecular patterns (DAMPs): two potential targets for COVID-19 treatment","volume":"2020","author":"Cicco","year":"2020","journal-title":"Mediators Inflammation"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.754127","article-title":"Divergent COVID-19 disease trajectories predicted by a DAMP-centered immune network model","volume":"12","author":"Day","year":"2021","journal-title":"Front Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.07.21267179","article-title":"Significantly elevated antibody levels and neutralization titers in nursing home residents after SARS-CoV-2 BNT162b2 mRNA booster vaccination","author":"Canaday","year":"2021","journal-title":"medRxiv"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01355-0","article-title":"Delayed production of neutralizing antibodies correlates with fatal COVID-19","volume":"27","author":"Lucas","year":"2021","journal-title":"Nat Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s42003-020-01526-8","article-title":"The kinetics of humoral response and its relationship with the disease severity in COVID-19","volume":"3","author":"Ren","year":"2020","journal-title":"Commun Biol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S304190","article-title":"Association of early inflammation with age and asymptomatic disease in COVID-19","volume":"14","author":"Xie","year":"2021","journal-title":"J Inflammation Res"},{"key":"B62","volume-title":"Therapeutics and COVID-19: living guideline, 22 april 2022","year":"2022"},{"key":"B63","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12933-022-01579-5","article-title":"Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID\/Post-Acute Sequelae of COVID-19 (PASC)","volume":"21","author":"Pretorius","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.698169","article-title":"Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms","volume":"12","author":"Proal","year":"2021","journal-title":"Front Microbiol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm2052","article-title":"Nervous system consequences of COVID-19","volume":"375","author":"Spudich","year":"2022","journal-title":"Science"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-022-05146-9","article-title":"Herpesvirus infections and post-COVID-19 manifestations: a pilot observational study","volume":"42","author":"Zubchenko","year":"2022","journal-title":"Rheumatol Int"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19105993","article-title":"Clinical and socio-demographic variables associated with the diagnosis of long COVID syndrome in youth: A population-based study","volume":"19","author":"Merzon","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2022.888232","article-title":"The pathobiology of myalgic encephalomyelitis\/chronic fatigue syndrome: the case for neuroglial failure","volume":"16","author":"Renz-Polster","year":"2022","journal-title":"Front Cell Neurosci"},{"key":"B69","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.cell.2022.01.014","article-title":"Multiple early factors anticipate post-acute COVID-19 sequelae","volume":"185","author":"Su","year":"2022","journal-title":"Cell"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01810-6","article-title":"Unexplained post-acute infection syndromes","volume":"28","author":"Choutka","year":"2022","journal-title":"Nat Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-065083","article-title":"Short-term and long-term impacts of COVID-19 on economic vulnerability: a population-based longitudinal study (COVIDENCE UK)","volume":"12","author":"Williamson","year":"2022","journal-title":"BMJ Open"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25731","article-title":"Evolutionary history, potential intermediate animal host, and cross-species analyses of SARS-CoV-2","volume":"92","author":"Li","year":"2020","journal-title":"J Med Virol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2004973","article-title":"Aerosol and surface stability of SARS-coV-2 as compared with SARS-coV-1","volume":"382","author":"van Doremalen","year":"2020","journal-title":"N Engl J Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0260287","article-title":"Protective measures are associated with the reduction of transmission of COVID-19 in Bangladesh: A nationwide cross-sectional study","volume":"16","author":"Sharif","year":"2021","journal-title":"PloS One"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3390\/v12030254","article-title":"Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-coV-2) based on SARS-coV immunological studies","author":"Ahmed","year":"2020","journal-title":"Viruses"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.714170","article-title":"Efficacy, immunogenicity and safety of COVID-19 vaccines: A systematic review and meta-analysis","volume":"12","author":"Sharif","year":"2021","journal-title":"Front Immunol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41541-021-00336-1","article-title":"Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2","volume":"6","author":"McDonald","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-021-04910-7","article-title":"Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly","volume":"41","author":"Seyahi","year":"2021","journal-title":"Rheumatol Int"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05547-w","article-title":"COVID-19 vaccination in immunocompromised patients","volume":"40","author":"Sonani","year":"2021","journal-title":"Clin Rheumatol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1177\/0846537120913033","article-title":"CT imaging and differential diagnosis of COVID-19","volume":"71","author":"Dai","year":"2020","journal-title":"Can Assoc Radiol J"},{"key":"B81","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1186\/s12879-021-06663-x","article-title":"What about the others: differential diagnosis of COVID-19 in a German emergency department","volume":"21","author":"Fistera","year":"2021","journal-title":"BMC Infect Dis"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-020-11061-5","article-title":"Detection technologies and recent developments in the diagnosis of COVID-19 infection","volume":"105","author":"Rai","year":"2021","journal-title":"Appl Microbiol Biotechnol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial","volume":"324","author":"Spinner","year":"2020","journal-title":"JAMA"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of covid-19 - final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N Engl J Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102685","article-title":"Bamlanivimab plus etesevimab in mild or moderate covid-19","volume":"385","author":"Dougan","year":"2021","journal-title":"N Engl J Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a neutralizing antibody cocktail, in outpatients with covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N Engl J Med"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-coV-2 neutralizing antibody LY-coV555 in outpatients with covid-19","volume":"384","author":"Chen","year":"2021","journal-title":"N Engl J Med"},{"key":"B91","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1001\/jama.2021.8828","article-title":"Effect of bamlanivimab vs placebo on incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities: A randomized clinical trial","volume":"326","author":"Cohen","year":"2021","journal-title":"JAMA"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101643","article-title":"Tofacitinib in patients hospitalized with covid-19 pneumonia","volume":"385","author":"Guimaraes","year":"2021","journal-title":"N Engl J Med"},{"key":"B93","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jaci.2020.05.019","article-title":"Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial","volume":"146","author":"Cao","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031304","article-title":"A randomized trial of convalescent plasma in covid-19 severe pneumonia","volume":"384","author":"Simonovich","year":"2021","journal-title":"N Engl J Med"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.o1045","article-title":"A living WHO guideline on drugs for covid-19","volume":"377","year":"2022","journal-title":"BMJ"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA120.013679","article-title":"Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency","volume":"295","author":"Gordon","year":"2020","journal-title":"J Biol Chem"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-020-00671-y","article-title":"Emerging treatment strategies for COVID-19 infection","volume":"21","author":"Gavriatopoulou","year":"2021","journal-title":"Clin Exp Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100867","article-title":"Decoding molnupiravir-induced mutagenesis in SARS-CoV-2","volume":"297","author":"Menendez-Arias","year":"2021","journal-title":"J Biol Chem"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100770","article-title":"Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template","volume":"297","author":"Gordon","year":"2021","journal-title":"J Biol Chem"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/s41594-021-00651-0","article-title":"Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis","volume":"28","author":"Kabinger","year":"2021","journal-title":"Nat Struct Mol Biol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab361","article-title":"Molnupiravir inhibits replication of the emerging SARS-coV-2 variants of concern in a hamster infection model","volume":"224","author":"Abdelnabi","year":"2021","journal-title":"J Infect Dis"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2022.105252","article-title":"Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern","volume":"198","author":"Vangeel","year":"2022","journal-title":"Antiviral Res"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12020393","article-title":"Real-world clinical outcomes of molnupiravir for the treatment of mild to moderate COVID-19 in adult patients during the dominance of the omicron variant: A meta-analysis","author":"Huang","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1010693107","article-title":"Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir","volume":"107","author":"Sevrioukova","year":"2010","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2380-z","article-title":"Human neutralizing antibodies elicited by SARS-CoV-2 infection","volume":"584","author":"Ju","year":"2020","journal-title":"Nature"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000651","article-title":"Monoclonal antibodies for the prevention and treatment of COVID-19 disease in patients with hematological Malignancies: two case reports and a literature review","volume":"5","author":"Klank","year":"2021","journal-title":"Hemasphere"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109682","article-title":"Subcutaneous REGEN-COV antibody combination to prevent covid-19","volume":"385","author":"O'Brien","year":"2021","journal-title":"N Engl J Med"},{"key":"B110","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/20477724.2021.2024030","article-title":"Bamlanivimab and Etesevimab administered in an outpatient setting for SARS-CoV-2 infection","volume":"116","author":"Bavaro","year":"2022","journal-title":"Pathog Glob Health"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab522","article-title":"Early monoclonal antibody administration can reduce both hospitalizations and mortality in high-risk outpatients with coronavirus disease 2019 (COVID-19)","volume":"74","author":"Jenks","year":"2022","journal-title":"Clin Infect Dis"},{"key":"B112","unstructured":"Anti-interleukin-6 therapies for hospitalized patients with COVID-19: a protocol for a prospective meta-analysis of randomized trials"},{"key":"B113","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jama.2021.11330","article-title":"Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis","volume":"326","author":"Shankar-Hari","year":"2021","journal-title":"JAMA"},{"key":"B114","unstructured":"Bethesda (MDClinicalTrials.gov National Library of Medicine (USStudy to assess the efficacy and safety of ruxolitinib in patients with COVID-19 associated cytokine storm (RUXCOVID)"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key276","article-title":"JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis","volume":"58","author":"Fragoulis","year":"2019","journal-title":"Rheumatol (Oxford)"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discovery"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-06022-5","article-title":"Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19)","volume":"46","author":"Alhazzani","year":"2020","journal-title":"Intensive Care Med"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0287-2020","article-title":"Updated guidance on the management of COVID-19: from an American Thoracic Society\/European Respiratory Society coordinated International Task Force (29 July 2020)","volume":"29","author":"Bai","year":"2020","journal-title":"Eur Respir Rev"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10081607","article-title":"Dexamethasone in patients hospitalized with COVID-19: whether, when and to whom","volume":"10","author":"Calzetta","year":"2021","journal-title":"J Clin Med"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.173947","article-title":"No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial","volume":"897","author":"Jamaati","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4940","article-title":"Convalescent plasma to treat COVID-19: possibilities and challenges","volume":"323","author":"Roback","year":"2020","journal-title":"JAMA"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.04.008","article-title":"Convalescent plasma therapy for persistent hepatitis E virus infection","volume":"71","author":"Ankcorn","year":"2019","journal-title":"J Hepatol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa1511812","article-title":"Evaluation of convalescent plasma for ebola virus disease in Guinea","volume":"374","author":"van Griensven","year":"2016","journal-title":"N Engl J Med"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc070359","article-title":"Treatment with convalescent plasma for influenza A (H5N1) infection","volume":"357","author":"Zhou","year":"2007","journal-title":"N Engl J Med"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1111\/trf.1660","article-title":"Comparability of six different immunoassays measuring SARS-CoV-2 antibodies with neutralizing antibody levels in convalescent plasma: From utility to prediction","volume":"61","author":"Lamikanra","year":"2021","journal-title":"Transfusion"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1172\/JCI150646","article-title":"A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19","volume":"131","author":"O'Donnell","year":"2021","journal-title":"J Clin Invest"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab289","article-title":"SARS-coV-2 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model","volume":"223","author":"Haagmans","year":"2021","journal-title":"J Infect Dis"},{"key":"B128","volume-title":"Physiology, blood volume","author":"Sharma","year":"2022"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2231","article-title":"Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis","volume":"374","author":"Siemieniuk","year":"2021","journal-title":"BMJ"},{"key":"B130","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1016\/S2213-2600(20)30084-9","article-title":"Staff safety during emergency airway management for COVID-19 in Hong Kong","volume":"8","author":"Cheung","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0000000000003296","article-title":"Intubation and ventilation amid the COVID-19 outbreak: wuhan's experience","volume":"132","author":"Meng","year":"2020","journal-title":"Anesthesiology"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503326","article-title":"High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure","volume":"372","author":"Frat","year":"2015","journal-title":"N Engl J Med"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.medin.2020.04.017","article-title":"Non-invasive mechanical ventilation and high-flow oxygen therapy in the COVID-19 pandemic: the value of a draw","volume":"45","author":"Gonzalez-Castro","year":"2021","journal-title":"Med Intensiva (Engl Ed)"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.03.043","article-title":"Preliminary findings on control of dispersion of aerosols and droplets during high-velocity nasal insufflation therapy using a simple surgical mask: implications for the high-flow nasal cannula","volume":"158","author":"Leonard","year":"2020","journal-title":"Chest"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.202004-317CME","article-title":"Mechanical-ventilation supply and options for the COVID-19 pandemic. Leveraging all available resources for a limited resource in a crisis","volume":"18","author":"Dar","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"B136","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1164\/rccm.202006-2405OC","article-title":"Case fatality rates for patients with COVID-19 requiring invasive mechanical ventilation","volume":"203","author":"Lim","year":"2021","journal-title":"A Meta-analysis. Am J Respir Crit Care Med"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2200198","article-title":"Coronavirus lung infection impairs host immunity against secondary bacterial infection by promoting lysosomal dysfunction","volume":"209","author":"Peng","year":"2022","journal-title":"J Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1116131\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T14:31:52Z","timestamp":1692023512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1116131\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,14]]},"references-count":137,"alternative-id":["10.3389\/fimmu.2023.1116131"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1116131","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,14]]},"article-number":"1116131"}}